世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Osteoporosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global osteoporosis drugs market is on a steady growth trajectory, driven by rising awareness, growing geriatric populations, and technological advancements in bone health management. The marke... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global osteoporosis drugs market is on a steady growth trajectory, driven by rising awareness, growing geriatric populations, and technological advancements in bone health management. The market is projected to grow at a CAGR of 4.34% during the forecast period from 2025 to 2032. From an estimated value of US$ 15 billion in 2025, it is expected to reach US$ 20.2 billion by the end of 2032.Market Insights Osteoporosis remains a major global health issue, particularly affecting older adults and postmenopausal women. The market continues to evolve with a significant rise in the adoption of innovative drugs and diagnostic methods. Recent FDA approvals of biosimilars and advanced therapeutic options are expanding treatment access and driving competition. Retail pharmacies are expected to dominate the market due to their widespread accessibility and trust among patients. Meanwhile, North America leads the global Analysis, followed closely by Europe and emerging regions such as Asia Pacific and Latin America. Market Drivers One of the key growth drivers is the demographic shift toward an aging population. As the risk of osteoporosis increases with age, the demand for effective bone-strengthening medications has surged. Clinical studies estimate that millions of individuals worldwide suffer from low bone mass or osteoporosis, elevating the demand for early diagnosis and pharmacological treatment. Cost-effectiveness of osteoporosis drugs in preventing expensive fractures—particularly hip fractures—is also fueling market adoption. Treatment with osteoporosis drugs significantly lowers the likelihood of fractures, making them a viable and economical solution for healthcare systems and patients alike. In addition, advancements in bone density diagnostic tools and routine osteoporosis screenings are improving early detection rates, thereby increasing treatment uptake. Business Opportunity The future of the osteoporosis drugs market lies in innovation. Companies are investing in research and development to launch novel therapeutics with better safety profiles and higher efficacy. Emerging treatments like romosozumab, which combine bone formation and resorption inhibition, showcase the market’s shift toward dual-action therapies. These next-generation biologics present promising opportunities for improved patient outcomes, especially for individuals at high risk of fractures. Another significant opportunity lies in emerging economies. As countries in Asia Pacific and Latin America improve healthcare infrastructure and access, the demand for osteoporosis treatments is set to increase. Rising disposable incomes, government initiatives, and awareness programs are expected to propel market penetration in these regions. Regional Analysis North America is set to retain its dominance in the osteoporosis drugs market due to high healthcare spending, robust infrastructure, and increased awareness of osteoporosis management. A large aging population and rapid adoption of advanced therapies such as biologics also support market growth in the region. Europe holds the second-largest share, with a strong pharmaceutical industry and broad patient awareness contributing to sustained growth. Asia Pacific and Latin America are witnessing rising demand, with governments investing in healthcare expansion and education about osteoporosis. These regions are expected to offer significant growth potential over the forecast period. The Middle East and Africa, while currently holding a smaller share, are gradually developing the healthcare systems needed to support osteoporosis treatment adoption. Key Players The global osteoporosis drugs market is highly competitive, with several major players actively enhancing their portfolios and exploring strategic collaborations. Leading companies in the market include: • Eli Lilly and Company • F. Hoffmann-La Roche Ltd. • Merck & Co, Inc. • Novartis AG • Amgen, Inc. • Novo Nordisk A/S • Actavis plc • Pfizer, Inc. • GlaxoSmithKline plc • Teva Pharmaceutical Industries Ltd • Enzene Biosciences Ltd • Theramex These companies are focusing on launching biosimilars, developing advanced biologics, and expanding into emerging markets to maintain a competitive edge. Market Segmentation By Drug • Bisphosphonates • Parathyroid Hormone Therapy Drugs • Calcitonin • Selective Estrogen Receptor Modulators (SERMs) • RANK Ligand Inhibitors By Distribution Channel • Retail Pharmacies • Hospital Pharmacies • Online Sales By Region • North America • Latin America • Europe • Asia Pacific • Oceania • The Middle East and Africa Table of Contents1. Executive Summary1.1. Global Osteoporosis Drugs Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2025 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. Porter’s Five Forces Analysis 2.5. COVID-19 Impact Analysis 2.5.1. Supply 2.5.2. Demand 2.6. Impact of Ukraine-Russia Conflict 2.7. Economic Overview 2.7.1. World Economic Projections 2.8. PESTLE Analysis 3. Global Osteoporosis Drugs Market Outlook, 2019-2032 3.1. Global Osteoporosis Drugs Market Outlook, by Drug, Value (US$ Bn), 2019-2032 3.1.1. Key Highlights 3.1.1.1. Bisphosphonates 3.1.1.2. Parathyroid Hormone Therapy Drugs 3.1.1.3. Calcitonin 3.1.1.4. Selective Estrogen Receptors Modulators (SERMs) 3.1.1.5. RANK Ligand Inhibitors 3.2. Global Osteoporosis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032 3.2.1. Key Highlights 3.2.1.1. Retail Pharmacies 3.2.1.2. Hospital Pharmacies 3.2.1.3. Online Sales 3.3. Global Osteoporosis Drugs Market Outlook, by Region, Value (US$ Bn), 2019-2032 3.3.1. Key Highlights 3.3.1.1. North America 3.3.1.2. Europe 3.3.1.3. Asia Pacific 3.3.1.4. Latin America 3.3.1.5. Middle East & Africa 4. North America Osteoporosis Drugs Market Outlook, 2019-2032 4.1. North America Osteoporosis Drugs Market Outlook, by Drug, Value (US$ Bn), 2019-2032 4.1.1. Key Highlights 4.1.1.1. Bisphosphonates 4.1.1.2. Parathyroid Hormone Therapy Drugs 4.1.1.3. Calcitonin 4.1.1.4. Selective Estrogen Receptors Modulators (SERMs) 4.1.1.5. RANK Ligand Inhibitors 4.2. North America Osteoporosis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032 4.2.1. Key Highlights 4.2.1.1. Retail Pharmacies 4.2.1.2. Hospital Pharmacies 4.2.1.3. Online Sales 4.3. North America Osteoporosis Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032 4.3.1. Key Highlights 4.3.1.1. U.S. Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 4.3.1.2. U.S. Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 4.3.1.3. Canada Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 4.3.1.4. Canada Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 4.3.2. BPS Analysis/Market Attractiveness Analysis 5. Europe Osteoporosis Drugs Market Outlook, 2019-2032 5.1. Europe Osteoporosis Drugs Market Outlook, by Drug, Value (US$ Bn), 2019-2032 5.1.1. Key Highlights 5.1.1.1. Bisphosphonates 5.1.1.2. Parathyroid Hormone Therapy Drugs 5.1.1.3. Calcitonin 5.1.1.4. Selective Estrogen Receptors Modulators (SERMs) 5.1.1.5. RANK Ligand Inhibitors 5.2. Europe Osteoporosis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032 5.2.1. Key Highlights 5.2.1.1. Retail Pharmacies 5.2.1.2. Hospital Pharmacies 5.2.1.3. Online Sales 5.3. Europe Osteoporosis Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032 5.3.1. Key Highlights 5.3.1.1. Germany Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 5.3.1.2. Germany Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 5.3.1.3. U.K. Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 5.3.1.4. U.K. Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 5.3.1.5. France Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 5.3.1.6. France Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 5.3.1.7. Italy Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 5.3.1.8. Italy Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 5.3.1.9. Turkey Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 5.3.1.10. Turkey Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 5.3.1.11. Russia Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 5.3.1.12. Russia Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 5.3.1.13. Rest of Europe Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 5.3.1.14. Rest of Europe Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 5.3.2. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Osteoporosis Drugs Market Outlook, 2019-2032 6.1. Asia Pacific Osteoporosis Drugs Market Outlook, by Drug, Value (US$ Bn), 2019-2032 6.1.1. Key Highlights 6.1.1.1. Bisphosphonates 6.1.1.2. Parathyroid Hormone Therapy Drugs 6.1.1.3. Calcitonin 6.1.1.4. Selective Estrogen Receptors Modulators (SERMs) 6.1.1.5. RANK Ligand Inhibitors 6.2. Asia Pacific Osteoporosis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032 6.2.1. Key Highlights 6.2.1.1. Retail Pharmacies 6.2.1.2. Hospital Pharmacies 6.2.1.3. Online Sales 6.3. Asia Pacific Osteoporosis Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032 6.3.1. Key Highlights 6.3.1.1. China Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 6.3.1.2. China Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 6.3.1.3. Japan Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 6.3.1.4. Japan Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 6.3.1.5. South Korea Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 6.3.1.6. South Korea Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 6.3.1.7. India Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 6.3.1.8. India Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 6.3.1.9. Southeast Asia Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 6.3.1.10. Southeast Asia Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 6.3.1.11. Rest of Asia Pacific Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 6.3.1.12. Rest of Asia Pacific Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 6.3.2. BPS Analysis/Market Attractiveness Analysis 7. Latin America Osteoporosis Drugs Market Outlook, 2019-2032 7.1. Latin America Osteoporosis Drugs Market Outlook, by Drug, Value (US$ Bn), 2019-2032 7.1.1. Key Highlights 7.1.1.1. Bisphosphonates 7.1.1.2. Parathyroid Hormone Therapy Drugs 7.1.1.3. Calcitonin 7.1.1.4. Selective Estrogen Receptors Modulators (SERMs) 7.1.1.5. RANK Ligand Inhibitors 7.2. Latin America Osteoporosis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032 7.2.1. Key Highlights 7.2.1.1. Retail Pharmacies 7.2.1.2. Hospital Pharmacies 7.2.1.3. Online Sales 7.3. Latin America Osteoporosis Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032 7.3.1. Key Highlights 7.3.1.1. Brazil Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 7.3.1.2. Brazil Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 7.3.1.3. Mexico Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 7.3.1.4. Mexico Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 7.3.1.5. Argentina Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 7.3.1.6. Argentina Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 7.3.1.7. Rest of Latin America Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 7.3.1.8. Rest of Latin America Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 7.3.2. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Osteoporosis Drugs Market Outlook, 2019-2032 8.1. Middle East & Africa Osteoporosis Drugs Market Outlook, by Drug, Value (US$ Bn), 2019-2032 8.1.1. Key Highlights 8.1.1.1. Bisphosphonates 8.1.1.2. Parathyroid Hormone Therapy Drugs 8.1.1.3. Calcitonin 8.1.1.4. Selective Estrogen Receptors Modulators (SERMs) 8.1.1.5. RANK Ligand Inhibitors 8.2. Middle East & Africa Osteoporosis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032 8.2.1. Key Highlights 8.2.1.1. Retail Pharmacies 8.2.1.2. Hospital Pharmacies 8.2.1.3. Online Sales 8.3. Middle East & Africa Osteoporosis Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032 8.3.1. Key Highlights 8.3.1.1. GCC Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 8.3.1.2. GCC Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 8.3.1.3. South Africa Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 8.3.1.4. South Africa Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 8.3.1.5. Egypt Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 8.3.1.6. Egypt Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 8.3.1.7. Nigeria Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 8.3.1.8. Nigeria Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 8.3.1.9. Rest of Middle East & Africa Osteoporosis Drugs Market by Drug, Value (US$ Bn), 2019-2032 8.3.1.10. Rest of Middle East & Africa Osteoporosis Drugs Market Distribution Channel, Value (US$ Bn), 2019-2032 8.3.2. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Product vs Distribution Channel Heatmap 9.2. Manufacturer vs Distribution Channel Heatmap 9.3. Company Market Share Analysis, 2025 9.4. Competitive Dashboard 9.5. Company Profiles 9.5.1. Eli Lilly and Company 9.5.1.1. Company Overview 9.5.1.2. Product Portfolio 9.5.1.3. Financial Overview 9.5.1.4. Business Strategies and Development 9.5.2. F. Hoffmann-La Roche Ltd. 9.5.2.1. Company Overview 9.5.2.2. Product Portfolio 9.5.2.3. Financial Overview 9.5.2.4. Business Strategies and Development 9.5.3. Merck & Co, Inc. 9.5.3.1. Company Overview 9.5.3.2. Product Portfolio 9.5.3.3. Financial Overview 9.5.3.4. Business Strategies and Development 9.5.4. Novartis AG 9.5.4.1. Company Overview 9.5.4.2. Product Portfolio 9.5.4.3. Financial Overview 9.5.4.4. Business Strategies and Development 9.5.5. Amgen, Inc. 9.5.5.1. Company Overview 9.5.5.2. Product Portfolio 9.5.5.3. Financial Overview 9.5.5.4. Business Strategies and Development 9.5.6. Novo Nordisk A/S 9.5.6.1. Company Overview 9.5.6.2. Product Portfolio 9.5.6.3. Financial Overview 9.5.6.4. Business Strategies and Development 9.5.7. Actavis plc 9.5.7.1. Company Overview 9.5.7.2. Product Portfolio 9.5.7.3. Financial Overview 9.5.7.4. Business Strategies and Development 9.5.8. Pfizer, Inc. 9.5.8.1. Company Overview 9.5.8.2. Product Portfolio 9.5.8.3. Financial Overview 9.5.8.4. Business Strategies and Development 9.5.9. GlaxoSmithKline plc 9.5.9.1. Company Overview 9.5.9.2. Product Portfolio 9.5.9.3. Financial Overview 9.5.9.4. Business Strategies and Development 9.5.10. Teva Pharmaceutical Industries Ltd 9.5.10.1. Company Overview 9.5.10.2. Product Portfolio 9.5.10.3. Financial Overview 9.5.10.4. Business Strategies and Development 9.5.11. Enzene Biosciences Ltd 9.5.11.1. Company Overview 9.5.11.2. Product Portfolio 9.5.11.3. Financial Overview 9.5.11.4. Business Strategies and Development 9.5.12. Theramex 9.5.12.1. Company Overview 9.5.12.2. Product Portfolio 9.5.12.3. Financial Overview 9.5.12.4. Business Strategies and Development 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療IT）の最新刊レポート
Fairfield Market Research社の ヘルスケアIT分野 での最新刊レポート
本レポートと同じKEY WORD（osteoporosis drugs）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
